Key Takeaways
At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of...
WASHINGTON, July 29, 2025 /PRNewswire/ -- President Trump's "Big, Beautiful Bill" became law on July 4. Weeks later, journalists are still answering the big,...
Delivered sequential net sales growth across all segments, despite negative consumer sentiment impacting global demandDelivered significant cost take out of 100 basis points or...
Denver campus scheduled to open in early 2026 and will occupy 60,000 square feet
DENVER, July 28, 2025 /PRNewswire/ -- Concorde Career Colleges, the healthcare education...
NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”2
LEBANON, Ore., July 24, 2025 /PRNewswire/ -- Western University of Health Sciences' College of Osteopathic Medicine of the Pacific-Northwest will be named the Heatherington...
Phillips brings 20+ years of experience in finance across various industries
DENVER, July 24, 2025 /PRNewswire/ -- Today, Delta Dental of Colorado (DDCO) announced the...
HOUSTON, July 23, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of...